Metsera (NASDAQ:MTSR) Stock Price Up 7.4% – Here’s Why

Metsera, Inc. (NASDAQ:MTSR) was up 7.4% on Tuesday . The company traded as high as $20.00 and last traded at $19.53. Approximately 178,578 shares were traded during trading, a decline of 77% from the average daily volume of 780,994 shares. The stock had previously closed at $18.18.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on MTSR shares. Guggenheim assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price on the stock. Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating on the stock. Bank of America started coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating on the stock.

Metsera Stock Up 2.3 %

The company’s fifty day moving average is $25.25.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.